Sticky fingers

New breed of jewel thief stalks M&A world

Image
Reynolds Holding
Last Updated : Feb 23 2013 | 2:09 AM IST
A new breed of jewel thief is stalking the M&A world. Deals like IntercontinentalExchange’s $8.2 billion acquisition of NYSE Euronext include so-called “crown jewel” lockups, which hand over valuable assets even if a transaction falls through. Courts have looked askance at such side agreements, but they’re creeping back. The potential benefits may rob shareholders of a higher bid.

Investor Ronald Perelman’s 1985 battle for Revlon prompted the Delaware Supreme Court to disallow lockups designed to thwart rather than encourage offers. Later decisions all but killed the tactic, and companies turned to breakup fees as protection against a deal’s collapse.

The financial crisis inspired a revival. In 2008, JPMorgan Chase won an option to buy the New York headquarters of Bear Stearns as the price for rescuing the collapsing investment bank. While acknowledging that the arrangement could dissuade better offers, a New York court ruled it reasonable in light of the dire circumstances.

That opened the door to a variety of lockups. Apple’s acquisition of AuthenTec last year called for an option to license technology from the fingerprint-sensor maker if the transaction tanked. Chinese genome firm BGI-Shenzhen’s bid for Complete Genomics included a bridge loan that could convert into the financially troubled target’s stock. And NYSE agreed that its European derivatives unit would use ICE exclusively to clear trades for two years, regardless of the outcome of their proposed merger.

It’s notable that each case helped the target, as law firm Kirkland & Ellis pointed out in a recent memo to clients. AuthenTec touted the benefits of associating with Apple and earning revenue from the license agreement. NYSE maintained that, thanks to ICE, it could avoid developing its own costly clearing system. In refusing to find the BGI deal unfair to other bidders, Delaware Judge Travis Laster stressed that the bridge loan would allow Complete Genomics to survive through the closing.

The benefits won’t always shield such arrangements from a legal challenge, especially if they’re designed to discourage other, potentially sweeter deals. As crown jewel lockups become more common, investors will need to remain vigilant. Someone eventually will attempt a royal fleecing.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 22 2013 | 9:21 PM IST

Next Story